

参考文献

- Orkin C, Oka S, Philibert P, et al. Long-acting cabotegravir + rilpivirine for HIV treatment: FLAIR week 96 results. CROI 2020. March 8-11, 2020. Boston, Massachusetts. Abstract 482.
- Overton ET, Richmond G, Rizzardni G, et al. Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2m study. CROI 2020. March 8-11, 2020. Boston, Massachusetts. Abstract 34.
- Palella FJ Jr, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. *AIDS*. 2014;28(3):335-344.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. December 18, 2019. Available at <http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf>. Accessed April 13, 2020.
- Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. *N Engl J Med*. 2014 Jul 17;371(3):234-47.
- Perez-Molina JA, Rubio R, Rivero A, et al. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial. *Lancet Infect Dis*. 2015;15(7):775-784.
- Pett SL, Amin J, Horban A, et al. Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study. *HIV Med*. 2018;19(1):65-71.
- Pierone G, Henegar C, Fusco J, et al. Two-drug Antiretroviral Regimens: An Assessment of Virologic Response and Durability Among Treatment-Experienced Persons Living With HIV in the OPERA® Observational Database. *J Int AIDS Soc*. 2019;22(12):e25418.
- Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase III study. *J Acquir Immune Defic Syndr*. 2016;71:530-537.